<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Skin Cancer Archives – Page 2 – MoleMax Systems</title>
	<atom:link href="https://molemaxsystems.com/tag/skin-cancer/feed/" rel="self" type="application/rss+xml" />
	<link></link>
	<description>Provide the best skin imaging device</description>
	<lastBuildDate>Tue, 23 Jun 2026 05:03:13 +0000</lastBuildDate>
	<language>en-AU</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://molemaxsystems.com/wp-content/uploads/2020/10/favicon.png</url>
	<title>Skin Cancer Archives – Page 2 – MoleMax Systems</title>
	<link></link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</title>
		<link>https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 05:03:13 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10065</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/">Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5c13e8"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Julien Anriot, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Siyuan Yan, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Clio Coste, MD, PhD; </span><span class="wi-fullname brand-fg">Philipp Tschandl, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Loic Verlingue, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Camille Andremasse, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Mona Amini-Adle, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Jean Luc Perrot, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Zongyuan Ge, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Harald Kittler, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Luc Thomas, MD, PhD</span></nav>
<h3><span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc "><br />
<strong>Key Points</strong></span></h3>
<p><strong>Question</strong>  How does artificial intelligence (AI) diagnostic performance compare to human dermatologists of varying experience for skin cancer detection in realistic clinical settings?</p>
<p><strong>Findings</strong>  In this diagnostic study of 652 physicians and 3 AI models evaluating 1117 cases, expert dermatologists (&gt;10 years of experience) achieved the highest accuracy (74.2%), considerably outperforming a modern unimodal foundation model (72.2%), which exceeded dermatologists with less than 1 year of experience (59.1%), while the first-generation convolutional neural network underperformed all readers (56.7%).</p>
<p><strong>Meaning</strong>  Future practice should integrate human-AI collaboration, with AI supporting less experienced clinicians and providing expert triage assistance and help to minimize fatigue-related diagnostic errors.</p>
<p>To read further on this article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2849416?guestAccessKey=0150ca00-9e91-4991-91bc-c92587ac78fb&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-recommended-tfl_&amp;utm_term=061726" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/">Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</title>
		<link>https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 00:33:36 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9963</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5c680d"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Youyou Zhou, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Weiming Zhong, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xulei Liu, MBBS; </span>Jianglin Zhang, MD, PhD</nav>
<p>&nbsp;</p>
<p>Malignant skin cancers impose an escalating and heterogeneous health burden worldwide.<sup>1</sup> Using the Global Burden of Disease (GBD) 2023 database,<sup>2</sup> we summarize these cancers’ epidemiology, subgroup patterns, and projections to 2050.</p>
<div class="h3 cb section-type-section ">
<h3 class="heading-text thm-col sb-sc"><strong>Methods</strong></h3>
</div>
<p class="para">We analyzed GBD 2023 estimates (1990-2023) for malignant melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. Outcomes included prevalence and disability-adjusted life-years (DALYs; years of life lost due to premature death plus years lived with disability). Subgroup analyses were conducted by sex, age group, and Sociodemographic Index (SDI; range, 0-1), defined as the geometric mean of indices of fertility in those younger than 25 years, education among those aged 15 years and older, and lag-distributed income per capita. Projections to 2050 used a bayesian age-period-cohort (BAPC) model, a bayesian hierarchical framework that jointly estimates age, period, and cohort effects and provides uncertainty intervals. For basal cell carcinoma, we excluded the 2005 to 2009 surveillance-artifact period and fit projections using 2010 to 2023 data. Additional methods are provided in the eMethods in Supplement 1. This study was deemed to be not human participant research by Shenzhen People’s Hospital; therefore, institutional review board approval and informed consent were not required.</p>
<p>To read this article in full <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848888?guestAccessKey=2634ca35-bbf2-434d-972c-06ce8df175f5&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=051326" target="_blank" rel="noopener">please click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</title>
		<link>https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 26 May 2026 02:46:59 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9900</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/">Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5cd813"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="wi-fullname brand-fg">Yin Li, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Robert A. Swerlick, MD</span></p>
<div class="h3 cb section-type-abstract decorated-hed ">
<h3 class="heading-text thm-col sb-sc"><strong>Abstract</strong></h3>
</div>
<div id="AbstractSection">
<p><strong>Importance</strong>  Periodic comprehensive skin examinations of asymptomatic individuals are widely accepted by dermatologists and the public, resulting in deployment of skin cancer (SC) surveillance practices that may include patients at low risk for SC.</p>
<p><strong>Objective</strong>  To define the demographics, SC risk factors, and near-term outcomes of asymptomatic individuals seeking comprehensive skin examinations.</p>
<p><strong>Design, Setting, and Participants</strong>  This cross-sectional study is a secondary analysis of data collected through a routine, previsit survey completed by patients who visited the Emory Healthcare Dermatology Clinic between March 2021 and October 2022. This study involved new patients who had no specific skin complaints and requested a general skin examination because they had general concerns about SC. Data were analyzed between from July to December 2025.</p>
<p><strong>Main Outcomes and Measures</strong>  The main objective was to identify patients at higher risk for SC development by evaluating characteristics including demographics and SC risk factors including skin phototype, eye and hair color, and family and personal history of SC. The number needed to examine to diagnose 1 SC was calculated for the entire cohort and for subgroups.</p>
<p><strong>Results</strong>  A total of 1074 new patients who noted no skin complaints but sought examinations for concerns about SC were identified (mean [SD] age, 50.3 [15.9] years; 643 [59.9%] female). Of these patients, 186 reported a personal history of SC, with the percentage reporting a history of SC increasing with age. Among those reporting SC history, 184 (99.5%) had skin phototypes I through III. Overall, 131 patients (12.2%) underwent 146 skin biopsies, and 38 SCs were diagnosed. Three patients younger than 50 years were diagnosed with SC, and 37 of 38 SCs were diagnosed in patients with skin types I through III. The number needed to be examined to diagnose 1 SC was 181 in patients 50 years or younger and 7 in patients 70 years or older. The number needed to examine for patients with and without a history of SC was 12 and 52, respectively.</p>
<p><strong>Conclusions and Relevance</strong>  This study found that populations of new patients without specific skin complaints seeking care for SC surveillance may contain substantial percentages of people at low risk for diagnosis of SC. Implementation of simple triage criteria for asymptomatic patients seeking SC surveillance based on age, skin phototype, and SC history could select for patients at substantially higher risk for SC diagnosis.</p>
<p>To read the full article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848896?guestAccessKey=e667353f-cfd2-411f-b6a8-9108619aa0e4&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=052026" target="_blank" rel="noopener">click here</a>.</p>
</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/">Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</title>
		<link>https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 12 May 2026 00:26:00 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermoscopy]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9679</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/">Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5d3957"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Giuseppe Argenziano, Giulia Briatico, Eugenia Veronica Di Brizzi, Camila Scharf, Gabriella Brancaccio, Elvira Moscarella, Maria Maddalena Nicoletti, Pasquale Verolino, Aimilios Lallas, Harald Kittler</p>
<p>&nbsp;</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: The recent WHO classification of melanocytic tumors introduces a refined molecular and histopathological framework suggesting distinct pathways and precursor lesions for all melanoma subtypes. While conceptually appealing, its clinical applicability is increasingly questioned.</p>
<p><strong>Objectives</strong>: This review critically examines the transformation theory from benign nevi to melanoma, highlighting inconsistencies between the proposed models and real-life practice.</p>
<p><strong>Methods</strong>: Through illustrative cases and key epidemiological evidence, we evaluated the validity of current models proposing intermediate lesions in melanoma development.</p>
<p><strong>Results</strong>: We argue that most melanomas arise de novo and that the so-called intermediate lesions, such as dysplastic nevi and atypical Spitz tumors, may mimic melanoma but are not true biological precursors.</p>
<p><strong>Conclusions</strong>: We propose a simplified, clinically oriented reclassification of melanocytic lesions based on morphologic ambiguity and actual behavior, aiming to guide therapeutic decisions and reduce di-agnostic overinterpretation.</p>
<p>To access the full article please <a href="https://dpcj.org/index.php/dpc/article/view/6994/3276" target="_blank" rel="noopener">click here</a>.</p>
<p>&nbsp;</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/">Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</title>
		<link>https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 28 Apr 2026 04:58:45 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9638</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/">Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5d9ba9"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span style="color: #000000;"><span class="wi-fullname brand-fg">Maya Mundada, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xiaochen Zhong, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Alexandra So, BS; </span><a class="meta-authors--etal td-u stats-meta-authors--etal" style="color: #000000;" tabindex="0" aria-label="et al"><span aria-hidden="true">et al</span></a></span></p>
	</div>
</div>




<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<h3><strong><span style="text-decoration: underline;">Key Points</span></strong></h3>
<p>&nbsp;</p>
<p><strong>Question</strong>  What demographic, clinical, and pathological characteristics are associated with the time to recurrence of localized melanomas?</p>
<p><strong>Findings</strong>  In this cohort study of 1092 individuals diagnosed with stage IA to IIC melanomas, tumor ulceration, thickness, location on the face or scalp or neck compared with the arms, neurotropism, lymphovascular invasion, and presence of mitoses were associated with time to melanoma recurrence in multivariable analysis.</p>
<p><strong>Meaning</strong>  Results of this study suggest that factors in addition to melanoma ulceration and thickness provide an important guide for patient surveillance and counseling about potential recurrence.</p>
<p>To read more on this article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2845561?guestAccessKey=9161d274-2282-48bd-9ffc-a83fd3d060c7&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=etoc-tfl_&amp;utm_term=041626" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/">Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Training Primary Care Practitioners In Dermoscopy Diagnostic Algorithms Enhances Diagnostic Accuracy and Triage of Suspected Skin Cancer: Scoping Review Evidence</title>
		<link>https://molemaxsystems.com/training-primary-care-practitioners-in-dermoscopy-diagnostic-algorithms-enhances-diagnostic-accuracy-and-triage-of-suspected-skin-cancer-scoping-review-evidence/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 10 Mar 2026 01:32:33 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Dermatoscope benefits]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9259</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/training-primary-care-practitioners-in-dermoscopy-diagnostic-algorithms-enhances-diagnostic-accuracy-and-triage-of-suspected-skin-cancer-scoping-review-evidence/">Training Primary Care Practitioners In Dermoscopy Diagnostic Algorithms Enhances Diagnostic Accuracy and Triage of Suspected Skin Cancer: Scoping Review Evidence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5deff6"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Alexandre Ladet, Sandra Lawton, Michael J Boffa</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: In many Western countries, access to a dermatologist can be difficult, while the incidence of skin cancer has risen steadily over the past 50 years.</p>
<p><strong>Objective</strong>: We reviewed the published literature to determine whether training primary care practitioners (PCPs) in dermoscopy through brief interventions based on diagnostic algorithms could improve patient care by improving their diagnostic accuracy of suspect lesions.</p>
<p><strong>Methods</strong>: A scoping review of the literature was conducted, focusing on studies published in the period 2003–2023 that assessed the ability of low-experienced PCPs to triage suspicious dermatological lesions using dermoscopic diagnostic algorithms. Regarding outcomes, we focused on quantitative variables relevant to screening practice in general practice, including sensitivity, specificity, referrals to specialists, and unnecessary lesion excisions.</p>
<p><strong>Results</strong>: Of the 926 studies initially identified, 13 were eventually selected: 10 cross-sectional observational studies and three randomized controlled trials. The studies were carried out in North America (N=6), Western Europe (N=4), and Australia (N=3). There was heterogeneity in the training interventions and the criteria used to assess diagnostic accuracy of PCPs after training; however, all studies showed an improvement in this parameter. The preferred algorithms for training PCPs were the 3-point checklist, the 7-point checklist, and the Triage Amalgamated Dermoscopy Algorithm.</p>
<div class="page" data-page-number="1" data-loaded="true">
<div class="textLayer"><strong>Conclusion</strong>: This review demonstrates the value of training PCPs in dermoscopic diagnostic algorithms through short courses to improve triage of suspicious lesions. However, it is still necessary to define a territorial organization, a precise working framework and limits for PCPs who take on this role.</div>
</div>
<div class="textLayer"></div>
<div>To read this article in full <a href="https://dpcj.org/index.php/dpc/article/view/5208/3208" target="_blank" rel="noopener">please click here</a>.</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/training-primary-care-practitioners-in-dermoscopy-diagnostic-algorithms-enhances-diagnostic-accuracy-and-triage-of-suspected-skin-cancer-scoping-review-evidence/">Training Primary Care Practitioners In Dermoscopy Diagnostic Algorithms Enhances Diagnostic Accuracy and Triage of Suspected Skin Cancer: Scoping Review Evidence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>One Clue, Two Outcomes: Benign vs Malignant Through Dermoscopy</title>
		<link>https://molemaxsystems.com/one-clue-two-outcomes-benign-vs-malignant-through-dermoscopy/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Mon, 09 Feb 2026 01:35:32 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermoscopy]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9119</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/one-clue-two-outcomes-benign-vs-malignant-through-dermoscopy/">One Clue, Two Outcomes: Benign vs Malignant Through Dermoscopy</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5e5ce4"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Patricija Girštautė, Melita Virpšaitė, Iveta Gylienė, Jorinta Jokubaitė, Tadas Raudonis</p>
<h3><strong>Introduction</strong></h3>
<p>Pyogenic granuloma is a common benign vascular lesion that can clinically and dermoscopically imitate melanoma and other tumors [1]. In our case, pyogenic granuloma and nodular melanoma exhibited dermoscopic similarities. Some dermoscopic patterns, which include characteristics such as a yellow collarette, a reddish homogenous area, and the presence of white rail lines, can aid in diagnosing pyogenic granuloma [12]. Even though pyogenic granuloma is benign, histology is still necessary, especially in cases where vas-cular structures are present, as melanoma cannot be ruled out [1,3].</p>
<p>To read this article <a href="https://dpcj.org/index.php/dpc/article/view/5780/3261" target="_blank" rel="noopener">please click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/one-clue-two-outcomes-benign-vs-malignant-through-dermoscopy/">One Clue, Two Outcomes: Benign vs Malignant Through Dermoscopy</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Intravascular cutaneous squamous cell carcinoma (cSCC): A rare histopathologic finding with potential prognostic significance</title>
		<link>https://molemaxsystems.com/intravascular-cutaneous-squamous-cell-carcinoma-cscc-a-rare-histopathologic-finding-with-potential-prognostic-significance/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 03:36:43 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9071</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/intravascular-cutaneous-squamous-cell-carcinoma-cscc-a-rare-histopathologic-finding-with-potential-prognostic-significance/">Intravascular cutaneous squamous cell carcinoma (cSCC): A rare histopathologic finding with potential prognostic significance</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5eb5df"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="corresponding-author" role="listitem"><span class="dropBlock">Alexa S. Podolsky, BS</span></span> ∙ <span role="listitem"><span class="dropBlock">Rachel Manci, MD</span></span> ∙ <span role="listitem"><span class="dropBlock">Samantha S. Sattler, MD</span></span> ∙ <span role="listitem"><span class="dropBlock">Daniel Lozeau, MD</span></span> ∙ <span role="listitem"><span class="dropBlock">Jordan B. Slutsky, MD</span></span></p>
<p>&nbsp;</p>
<h2>Introduction</h2>
<div id="p0010" role="paragraph">Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous malignancy, and its incidence continues to increase over time. While cSCC generally portends a favorable prognosis, significant morbidity and mortality are possible in its more advanced stages.<span class="dropBlock reference-citations"><a id="body-ref-sref1-1" class="reference-citations__ctrl" role="doc-biblioref" href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext#" data-xml-rid="bib1" aria-label="Reference 1" aria-expanded="false" data-db-target-for="sref1-1" aria-controls="sref1-1"><sup>1</sup></a></span> The high-risk prognostic factors currently described by the American Joint Committee on Cancer (AJCC) eighth edition and the Brigham and Women’s Hospital (BWH) include tumor diameter greater than 2-cm, depth of invasion beyond the subcutaneous fat, bony invasion, poor-differentiation, and perineural invasion.<span class="dropBlock reference-citations"><a id="body-ref-sref2" class="reference-citations__ctrl" role="doc-biblioref" href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext#" data-xml-rid="bib2" aria-label="Reference 2" aria-expanded="false" data-db-target-for="sref2" aria-controls="sref2"><sup>2</sup></a></span> Intravascular invasion of cSCC is a rare histopathologic finding that is not currently described in either cSCC staging guideline, yet may influence locoregional recurrence and patient prognosis.<span class="dropBlock reference-citations"><a id="body-ref-sref5-1" class="reference-citations__ctrl" role="doc-biblioref" href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext#" data-xml-rid="bib3 bib4 bib5" aria-expanded="false" data-db-target-for="sref5-1" aria-controls="sref5-1"><sup>3-5</sup></a></span> Herein, we present 2 cases of cSCC with intravascular invasion identified during Mohs micrographic surgery (MMS), summarize the prognostic data that are available to date, and provide management recommendations for surgical cases exhibiting this high-risk feature.</div>
<div role="paragraph"></div>
<div role="paragraph">To read the full article please <a href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext" target="_blank" rel="noopener">click here</a>.</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/intravascular-cutaneous-squamous-cell-carcinoma-cscc-a-rare-histopathologic-finding-with-potential-prognostic-significance/">Intravascular cutaneous squamous cell carcinoma (cSCC): A rare histopathologic finding with potential prognostic significance</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Nicotinamide for Skin Cancer Chemoprevention</title>
		<link>https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 06 Jan 2026 00:49:52 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8925</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/">Nicotinamide for Skin Cancer Chemoprevention</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c5f14a1"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Kimberly F. Breglio, MD, DPhil</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Katlyn M. Knox, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Jonathan Hwang, BS; </span><span class="wi-fullname brand-fg">Rachel Weiss, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Kyle Maas, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Siwei Zhang, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Lydia Yao, MS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Chris Madden, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Yaomin Xu, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Rebecca I. Hartman, MD, MPH</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Lee Wheless, MD, PhD</span></nav>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a3db1c5f3176"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<h3><strong><span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc ">Key Points</span></strong></h3>
<p><strong>Question</strong><br />
Does nicotinamide supplementation prevent skin cancer development?</p>
<p><strong>Findings</strong><br />
In this retrospective study of 33 822 veterans, there was a decreased risk of 3 types of skin cancer associated with use of nicotinamide. The magnitude of reduction was associated with the number of skin cancers before nicotinamide use.</p>
<p><strong>Meaning</strong><br />
The results of this study suggest that use of nicotinamide is associated with a reduced risk of skin cancer development.</p>
<p>To read more on this article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2838591?guestAccessKey=6322d137-7880-47b6-b03c-cdced6a243b1&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-recommended-tfl_&amp;utm_term=101525" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/">Nicotinamide for Skin Cancer Chemoprevention</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Pigment Network Analysis in Melanoma and Nevi: Retrospective Study from Snippets to Full Dermoscopic Images</title>
		<link>https://molemaxsystems.com/pigment-network-analysis-in-melanoma-and-nevi-retrospective-study-from-snippets-to-full-dermoscopic-images/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 09 Dec 2025 01:31:18 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8883</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/pigment-network-analysis-in-melanoma-and-nevi-retrospective-study-from-snippets-to-full-dermoscopic-images/">Pigment Network Analysis in Melanoma and Nevi: Retrospective Study from Snippets to Full Dermoscopic Images</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3db1c6036ed"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Noa Kremer, Isabella N. Dana, Emmanouil Chousakos, Larissa M. Pastore, Allan C. Halpern, Stephen W. Dusza, Jochen Weber; Ofer Reiter, Aimilios Lallas, Cristian Navarrete-Dechent, Ralph Braun, Harold S. Rabinovitz, Gustavo Carvalho, Rashek Kazi, Rozina B. Zeidan, Shirin Bajaj, Nicholas R. Kurtansky, Ashfaq A. Marghoob</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a3db1c6052c6"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<h3 class="_label"><strong>Abstract</strong></h3>
<p><strong>Introduction: </strong>Atypical network is a dermoscopic criterion that helps in the diagnosis of melanoma. Despite its importance, the interpretation of atypical networks varies widely among experts.</p>
<p><strong>Objective: </strong>This study examined the impact of viewing the whole lesion versus viewing foci of pigment network (i.e., snippets) in isolation from within the lesion on expert classification of pigment network in dermoscopic images.</p>
<p><strong>Method: </strong>Six dermoscopy experts, blinded to the diagnosis, each evaluated a total of 92 images (80 nevi and 12 melanomas) for the presence of typical versus atypical pigment network. While 57% of images had consistent classification of the network between whole lesion and snippets, 43% shifted the network classification between the snippet to the whole lesion view. Melanomas were more prone than nevi to intra-rater discrepancy between whole lesion and snippets (54.2% vs. 41.7%; odds ratio (OR): 1.65; 95% confidence interval (CI): 1.11–2.47). The inter-observer agreement was higher for the snippet view (65.22%) than for the whole lesion view (55%).</p>
<p><strong>Results: </strong>These findings suggest that both the objective morphology of the pigment network and the subjective interpretation of the network in context with other features within the lesion influence expert classification of pigment network.</p>
<p><strong>Conclusion: </strong>Factors such as the variability in the distribution, thickness, and color of network lines, overall pattern, and other dermoscopic structures likely contributed to the classification changes.</p>
<p>To read the full article please visit this site &#8211; <a href="https://dpcj.org/index.php/dpc/article/view/5700" target="_blank" rel="noopener">Dermatology Practical &amp; Conceptual</a></p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/pigment-network-analysis-in-melanoma-and-nevi-retrospective-study-from-snippets-to-full-dermoscopic-images/">Pigment Network Analysis in Melanoma and Nevi: Retrospective Study from Snippets to Full Dermoscopic Images</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
